Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 19/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27829924 | 1.00 | TOP1 (0.81) | TOP1MEN1KMT2A | |
| SCHEMBL9559783 | 0.95 | TOP1 (0.81) | TOP1MEN1KMT2A | |
| SCHEMBL17092799 | 0.94 | TOP1 (0.74) | TOP1MEN1KMT2A | |
| SCHEMBL17092808 | 0.94 | TOP1 (0.74) | TOP1MEN1KMT2A | |
| SCHEMBL9559944 | 0.93 | TOP1 (0.76) | TOP1MEN1KMT2A | |
| SCHEMBL31681864 | 0.93 | TOP1 (0.76) | TOP1MEN1KMT2A | |
| SCHEMBL17092806 | 0.92 | TOP1 (0.72) | TOP1MEN1KMT2A | |
| SCHEMBL17092802 | 0.91 | TOP1 (0.71) | TOP1MEN1KMT2A | |
| SCHEMBL17092798 | 0.91 | TOP1 (0.70) | TOP1MEN1KMT2A | |
| SCHEMBL18296783 | 0.90 | TOP1 (0.80) | TOP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208050-A1 | PROCESS FOR PREPARING IRINOTECAN | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-09-06 | — | — | US | claimed |
| EP-3030567-B1 | METHOD FOR THE SYNTHESIS OF IRINOTECAN | SYNBIAS PHARMA AG (CH) | 2016-09-14 | — | — | EP | disclosed |
| EP-2881396-A1 | Method for the synthesis of irinotecan | Synbias Pharma AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-8980909-B2 | HDAC inhibiting derivatives of camptothecin | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980909-B2 | HDAC inhibiting derivatives of camptothecin | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130281402-A1 | HDAC INHIBITING DERIVATIVES OF CAMPTOTHECIN | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281402-A1 | HDAC INHIBITING DERIVATIVES OF CAMPTOTHECIN | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2013-10-24 | — | — | US | disclosed |
| US-20070208050-A1 | PROCESS FOR PREPARING IRINOTECAN | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-09-06 | — | — | US | disclosed |
| US-20070208050-A1 | PROCESS FOR PREPARING IRINOTECAN | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-09-06 | — | — | US | disclosed |
| US-20070208050-A1 | PROCESS FOR PREPARING IRINOTECAN | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281402-A1 | HDAC INHIBITING DERIVATIVES OF CAMPTOTHECIN | HDAC1, HDAC11, HDAC2 | TOP1 40/4885MEN1 3024/4885KMT2A 106/4885 |
| US-20070208050-A1 | PROCESS FOR PREPARING IRINOTECAN | SI, TYMP, TOP1 | TOP1 3/4885MEN1 823/4885KMT2A 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.